CompletedNCT00318448
Zolpidem for insomnia in children with ADHD
About this title
Read the official source — NCT00318448Medication studyAges 6–17United States + Canada
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Bridgewater and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 201
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00318448
- Official title
Show the full official title
Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bridgewater, United States · Laval, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sanofi.
Did this study involve medication?
Yes. The study involved medication, including Zolpidem (SL800750).
Who was this study for?
Listed age limits: 6 years to 17 years.
